FOXO3 and acute lymphoblastic leukemia: Our data also indicate that in B-ALL, deletions of 6q may flag a metabolic vulnerability, which could be exploited by specific activation of FOXO3 or treatment with inhibitors of glycolysis such as the TXNIP agonist 3-O-methyleglucose [57].